Valuation: IDEAYA Biosciences, Inc.

Capitalization 2.98B 2.52B 2.32B 2.2B 4.07B 276B 4.14B 27.18B 10.66B 134B 11.17B 10.94B 471B P/E ratio 2026 *
-8.41x
P/E ratio 2027 * -9.98x
Enterprise value 1.95B 1.65B 1.52B 1.44B 2.67B 181B 2.72B 17.82B 6.99B 87.55B 7.32B 7.17B 309B EV / Sales 2026 *
53x
EV / Sales 2027 * 17.8x
Free-Float
98.96%
Yield 2026 *
-
Yield 2027 * -
Apr. 14 Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says MT
Apr. 14 Mizuho Raises Price Target on IDEAYA Biosciences to $52 From $46, Keeps Outperform Rating MT
Apr. 14 RBC Raises Price Target on IDEAYA Biosciences to $53 From $49, Keeps Outperform, Speculative Risk MT
Apr. 13 Ideaya Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial of Darovasertib in Combination with Crizotinib in First-Line Hla-A*02:01-Negative Metastatic Uveal Melanoma CI
Apr. 13 Wedbush Adjusts Price Target on IDEAYA Biosciences to $58 From $52, Maintains Outperform Rating MT
Apr. 13 IDEAYA Biosciences, Inc. - Special Call
Apr. 13 Top Premarket Gainers MT
Apr. 13 IDEAYA Biosciences Says Trial Evaluating Darovasertib With Crizotinib Achieves Primary Endpoint MT
Apr. 13 IDEAYA and Servier's eye cancer drug meets trial goal, paving way for FDA application RE
Apr. 10 Ideaya Biosciences to announce topline results from phase 2/3 Optimum-02 trial in metastatic uveal melanoma on Monday, April 13, 2026 RE
Apr. 09 Ideaya Biosciences Inc - enters clinical collaboration agreement with AstraZeneca on April 8, 2026 - SEC filing RE
Apr. 09 Ideaya Biosciences, Inc. And Astrazeneca Plc Enter Clinical Collaboration Agreement CI
Apr. 06 Ideaya Biosciences announces first-patient-in for Phase 1 trial of IDE574, a potential first-in class dual inhibitor of KAT6/7 to target multiple solid tumor indications, including breast, prostate, CRC, and lung cancer RE

Last Transcript: IDEAYA Biosciences, Inc.

1 day+4.31%
1 week+11.18%
Current month+1.77%
1 month-1.05%
3 months-5.39%
6 months+15.89%
Current year-1.91%
1 week 30.71
Extreme 30.71
38.1
1 month 29.57
Extreme 29.57
38.1
Current year 29.47
Extreme 29.468
39.28
1 year 16.81
Extreme 16.81
39.28
3 years 13.45
Extreme 13.45
47.74
5 years 8.14
Extreme 8.14
47.74
10 years 2.95
Extreme 2.95
47.74
Manager TitleAgeSince
Chief Executive Officer 51 2015-05-31
Chief Tech/Sci/R&D Officer 59 2022-11-20
Chief Tech/Sci/R&D Officer 61 2021-10-31
Director TitleAgeSince
Director/Board Member 51 2015-05-31
Chairman 68 -
Director/Board Member 71 2015-09-30
Change 5d. change 1-year change 3-years change Capi.($)
+4.31%+11.18%+98.54%+124.57% 2.98B
+2.22%+5.51%+0.78%-7.93% 48.69B
+0.99%+4.59%+40.22%+22.31% 35.92B
-0.43%+54.13%+304.33%+504.92% 31.26B
-0.72%+3.91%+35.55%+29.11% 29.77B
+2.62%+5.45%+22.62%-12.91% 29.62B
-6.22%-0.52%+3,641.35%+3,836.02% 14.18B
+0.63%+2.17%+48.12%+195.41% 15.1B
+0.96%+5.48%+75.71%+166.26% 14.87B
+0.87%+8.85%+40.89%+13.56% 14.5B
Average +0.52%+9.94%+430.81%+487.13% 23.69B
Weighted average by Cap. +0.62%+11.12%+283.19%+325.28%

Financials

2026 *2027 *
Net sales 36.82M 31.19M 28.7M 27.16M 50.33M 3.41B 51.22M 336M 132M 1.65B 138M 135M 5.82B 129M 109M 100M 94.83M 176M 11.9B 179M 1.17B 460M 5.77B 482M 472M 20.32B
Net income -364M -308M -283M -268M -497M -33.64B -506M -3.32B -1.3B -16.31B -1.36B -1.34B -57.47B -321M -272M -251M -237M -439M -29.75B -447M -2.93B -1.15B -14.42B -1.21B -1.18B -50.82B
Net Debt -1.03B -869M -800M -757M -1.4B -94.94B -1.43B -9.37B -3.67B -46.02B -3.85B -3.77B -162B -686M -581M -535M -506M -938M -63.49B -955M -6.26B -2.46B -30.78B -2.57B -2.52B -108B
Logo IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.
Employees
145
Date Price Change Volume
26-04-17 33.91 $ +4.31% 1,613,402
26-04-16 32.51 $ +1.03% 1,248,346
26-04-15 32.18 $ -0.53% 2,158,380
26-04-14 32.35 $ -1.43% 3,809,355
26-04-13 32.82 $ +7.61% 10,039,159
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
33.91USD
Average target price
52.81USD
Spread / Average Target
+55.74%

Quarterly revenue - Rate of surprise